1. Joshi SN, Wankhede KS, Jadhav SB, Pawar SS, Ahirrao VK, Bhawsar SB, Deshpande PK, Yeole RD, Patel MV (2013) A process for preparation of (2S,5R)-7-Oxo-6-sulphooxy-2-[Nʹ-((3R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza- bicyclo[3.2.1]octane. World Intellectual Property Organization: International application published under the patent cooperation treaty (PCT), Publication Number WO2014/135931
2. Patel MV, Deshpande PK, Bhawsar SB, Bhagwat SS, Jafri MA, Mishra A, Pavase L, Gupta S, Kale R, Joshi SN (2011) 1,6-diaza- bicyclo[3.2.1]octane-7-one derivatives and their use in treatment of bacterial infections. World Intellectual Property Organization: International application published under the patent cooperation treaty (PCT), Publication Number US2014/0148431A1
3. Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK (2017) WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother 61(5):e00072-17. https://doi.org/10.1128/AAC.00072-17
4. Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M (2017) WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother 72(6):1696–1703. https://doi.org/10.1093/jac/dkx050
5. Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N (2017) In vitro activity of cefepime/zidebactam (WCK 5222) against gramnegative bacteria. J Antimicrob Chemother 56(5):1373–1385. https://doi.org/10.1093/jac/dkw593